Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTM-001-ADC
- Development stage
- Preclinical
- Lead developer
- PTM Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
PTM-001-ADC is a preclinical-stage antibody-drug conjugate (ADC) being developed by PTM Therapeutics for the treatment of metastatic colon cancer and other solid tumors. The drug consists of a humanized monoclonal antibody (PTM-001) that targets a tumor-specific post-translational modification (PTM), specifically a glycan epitope on **CD44 variant 6 (CD44v6)**, which is highly expressed in colon adenocarcinoma and its metastatic satellites. The antibody is conjugated to the microtubule-disrupting cytotoxic agent **DM1 (mertansine)** via a non-cleavable **SMCC linker**. PTM-001-ADC has demonstrated potent cytotoxicity in colon cancer cell lines (e.g., Colo-205) and efficacy in xenograft models, showing superior tumor shrinkage compared to standard chemotherapy like irinotecan. The program is currently in preclinical development, with the company seeking partners for linker-toxin optimization.
- Other names
- PTM-001 ADCPTM001 ADCPTM 001 ADC
02
Targets
TUBB (Tubulin (alpha and beta subunits))CD44v6 (CD44 variant isoform 6)
Beyond the preview
Go deeper on PTM-001-ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTM-001-ADC.